Current research status of HLA in immune-related diseases

Bingnan Liu | Yuanyuan Shao | Rong Fu

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, PR China

Correspondence
Rong Fu, Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Rd, Heping District, Tianjin 300052, PR China.
Email: furong8369@tmu.edu.cn

Funding information
National Natural Science Foundation of China, Grant/Award Numbers: 81800119, 81800120, 81800125, 81900125, 81970115, 81970116

Abstract
Human leukocyte antigen (HLA), also known as human major histocompatibility complex (MHC), is encoded by the HLA gene complex, and is currently known to have the highest gene density and the most polymorphisms among human chromosomal areas. HLA is divided into class I antigens, class II antigens, and class III antigens according to distribution and function. Classical HLA class I antigens include HLA-A, HLA-B, and HLA-C; HLA class II antigens include HLA-DP, HLA-DQ, and HLA-DR; nonclassical HLA class I and II molecules include HLA-F, E, H, X, DN, DO, and DM; and others, such as complement, are class III antigens. HLA is closely related to the body's immune response, regulation, and surveillance and is of great significance in the study of autoimmune diseases, tumor immunity, organ transplantation, and reproductive immunity. HLA is an important research topic that bridges immunology and clinical diseases. With the development of research methods and technologies, there will be more discoveries and broader prospects.

KEYWORDS
HLA, immune-related diseases, MHC

1 | INTRODUCTION

Human leukocyte antigen (HLA), also known as human major histocompatibility complex (MHC), is encoded by the HLA gene complex. The HLA gene is located on the short arm of chromosome 6 (6p21.31), covering an area of 7.6 Mb and containing more than 250 genes with different functions, and is currently known to have the highest gene density and the most polymorphisms among human chromosomal areas. HLA is divided into class I antigens, class II antigens, and class III antigens according to distribution and function. Classical HLA class I antigens include HLA-A, HLA-B, and HLA-C; HLA class II antigens include HLA-DP, HLA-DQ, and HLA-DR; nonclassical HLA class I and II molecules include HLA-F, E, H, X, DN, DO, and DM; and others, such as complement, are class III antigens. HLA is closely related to the body's immune response, regulation, and surveillance and is of great significance in the study of autoimmune diseases, tumor immunity, organ transplantation, and reproductive immunity. This article reviews the current research status of HLA in immune-related diseases.

2 | AUTOIMMUNE BLOOD DISEASES

Autoimmune diseases account for a large proportion of blood system diseases, among which aplastic anemia (AA) is a typical autoimmune-mediated pancytopenia disease. In AA patients, the percentage of loss of heterozygosity of the short arm of chromosome 6 (6pLOH)
has been shown to reach 13%, significantly higher than that in normal healthy people (0.09%), and 6pLOH has been shown to directly lead to the haploid loss of HLA genes on 6p. The Japanese scholar Katagiri found that HLA allele deletions in 6pLOH(+) clones were concentrated in four alleles (HLA-A*02:01, A*02:06, A*31:01, and B*40:02) and that in 6613 Japanese AA patients, the expression of these four alleles was higher than that of other HLA genes. The high expression of these four HLA molecules in blood cells is considered a possible cause of cytotoxic T lymphocytes (CTL) killing. 6pLOH(+) clones evade immune attack due to the absence of HLA haplotypes and become the source of clonal haematopoiesis in patients with AA after receiving immunosuppressive therapy (IST). In a somatic mutation analysis of granulocytes from AA patients, haematopoietic stem progenitor cells (HSPCs) lacking HLA class I alleles maintained clonal haematopoiesis in AA patients in the absence of driver mutations or telomere shortening; driver mutations did not occur in HSPCs (unless HLA loss occurred after somatic mutations in HSPCs); and 6pLOH may provide HSPCs with somatic mutations a survival advantage, leading to the clonal expansion of mutant HSPCs. To understand the origin and clinical significance of HLA-allele-lacking leukocytes (HLA-LL) in AA patients due to 6pLOH, a research team used flow cytometry to detect the number and lineage classification of HLA-LL in 144 patients with AA. The results suggested that the clones that could escape from CTL attacks are haematopoietic progenitor cells (HPCs) instead of haematopoietic stem cells (HSCs). HPCs lack the ability to differentiate into lymphoid cells but can self-renew to support bone marrow production. Maruyama et al. proposed that the specific killing of HPCs by CTLs may not play a major role in the occurrence and development of AA but that the main role is the nonspecific inhibition of haematopoietic function by cytokines. Analysis of the response of AA patients with different genotypes to treatment showed that the response rate of HLA-LL(+) AA patients to IST was significantly higher than that of HLA-LL(−) AA patients and HLA-A homozygous patients, and that the survival rate without bone marrow failure of untreated HLA-LL(+)AA patients was also significantly higher than that of HLA-LL(−)AA patients and HLA-A homozygous patients.

On this basis, Zaimoku et al. studied the frequency of HLA allele loss in 312 AA patients and found that HLA-B*40:02 was the allele with the highest frequency of loss. In the granulocytes of AA patients, HLA-B*40:02 has high-frequency somatic mutations, which may come from 6pLOH(+) clones or from 6pLOH(−) clones. This result suggests that haematopoietic stem/progenitor cells present antigens to cytotoxic T cells via HLA-B, which plays a key role in the pathogenesis of AA, and that clonal haematopoiesis in AA comes from immune pressure selection. In addition, they successfully isolated T cell clones that can specifically kill HLA-B*40:02-positive haematopoietic cells from a 6pLOH(+) AA patient. Furthermore, Espinoza et al. induced pluripotent stem cells (iPSCs) in vitro for gene editing and found that haematopoietic stem cells derived from the iPSCs of AA patients with HLA-deficiency and wild-type haematopoietic stem cells showed similar haematopoietic abilities and that iPSC-HSCs lacking HLA-B4002 escaped specific T-cell attack. In this study, iPSCs from AA patients were injected and transplanted into nude mice to create an AA mouse model, and the same results were obtained through in vivo studies. In a follow-up study, among AA patients who did not carry HLA-B*40:02, B*54:01 was one of the three most common HLA alleles in 6pLOH(+) patients (29% [5/17]). To gain insight into the fundamental mechanism of clonal haematopoiesis caused by HSPCs-lacking HLA-B5401, HSPCs derived from iPSCs from a large number of AA patients lacking B5401 in monocytes were studied, leading to results similar to those of the above studies.

Recently, some researchers have used the super-high resolution, single-molecule, sequence-based typing (SS-SBT) method to detect 6pLOH in a patient with severe AA, and the detection rate for 6pLOH was the highest during granulocyte colony-stimulating factor (G-CSF) treatment. This result indicated that most of the neutrophil precursor cells stimulated by G-CSF had already developed LOH at the site of HLA damage. The SS-SBT method is a simple next-generation sequencing (NGS) method that can completely cover HLA alleles. In addition, recent studies on fetal and neonatal alloimmune thrombocytopenia (FNAIT) have shown that the HLA molecule encoded by HLA-DRA/DRB3*01:01 is very important in this immune response. This disease is caused by alloantibodies against human platelet antigen 1a (HPA-1a). The HLA-DRB3*01:01 allele has a significant dose-dependent effect on anti-HPA-1a levels, and maternal HLA-DRB3*01:01 alleles have a significant negative dose-dependent effect on neonatal platelet counts. HLA-DRB3*01:01 carrier status is not only an important immune risk factor but also has a significant impact on fetal/neonatal outcomes. The HPA-1a-related immunity risk for HPA-1a-positive infants born to HPA-1a-negative, HLA-DRB3*01:01-positive women is 25 times higher than that for infants born to HPA-1a and HLA-DRB3*01:01 double negative women. Therefore, the HLA-DRB3*01:01 classification can be used as a clinical tool for risk stratification of HPA-1a-negative pregnant women during consultation.
between the fetal or neonatal outcome of HPA-1a-immunized women and maternal HLA-DRB3*01:01 carrier status has been verified by prospective and retrospective studies.\(^{15-17}\) In addition, the effect of the HLA-DRB3*01:01 allele on the prognosis of the fetus or newborn may be mediated by different anti-HPA-1a antibody levels.\(^{18}\) There is a significant correlation between the level of HPA-1a in pregnant women and the prognosis of the fetus or new-born.\(^{19}\)

### 3 | CONNECTIVE TISSUE DISEASE

In rheumatoid arthritis (RA), HLA is the most important genetic risk factor, of which the HLA-DRB1 allele is the most important. HLA-DRB1 alleles, especially DR4 and DR1, encode the HLA-DRβ chain. HLA-DRβ contains 5-amino-acid sequence motifs (positions 70–74 share 5-amino-acid sequences, namely, QKRAA, QKRAA, and RRRAA), which are called shared epitopes (SEs) and are closely related to RA susceptibility.\(^{20,21}\) Anticitrullinated protein antibodies (ACPAs) are important RA disease markers. Patients carrying HLA-DRB1 alleles with SEs tend to be susceptible to ACPA-positive RA, and those not carrying HLA alleles with SEs tend to be susceptible to ACPA-negative RA. In SE-positive RA patients, the ACPA titer in patients with the DRB1*04 allele is higher than that in patients with the DRB1*01 allele.\(^{22,23}\) HLA-DRB1 encoding SEs not only increase the risk of RA but also increase the risk of early disease onset, more severe bone erosion, and ACPA. Moreover, the correlations between SEs and RA and between SEs and disease severity depend on the gene dose. Carrying 2 alleles encoding SEs is associated with a much higher risk of joint damage than is carrying 1 allele. In addition, the DRβ chains encoded by the alleles DRB1*01:03, DRB1*13:01, DRB1*13:02, and DRB1*04:02 have an opposite protective effect in RA.\(^{24,25}\) However, some scholars question the theory that SE-expressing HLA-DR molecules of RA patients present specific antigens because comparative analysis found that the eluted peptide antigens of different HLA-DR molecules expressing SEs have almost no overlapping similar fragments.\(^{26}\)

HLA is closely related to ethnicity and population in anthropological research, and similar findings have been found in RA research. Among European RA patients, DRB1*04:01, *04:04, *01:01, and *10:01 are the main alleles encoding SEs, and in East Asian patients, the most common SE-encoding allele is DRB1*04:05. Among the Pima, Tlingit, Yakima, and Chippewa Indians, the SE-encoding allele DRB1*14:02 is an important genetic risk factor for severe RA.\(^{27}\)

The genetic inheritance of DR and DQ loci presents high linkage disequilibrium, and RA-related DRB1 alleles are specifically expressed in haploids with specific DQ loci. For example, SE-encoding DRB1*04:01 appears in haploids containing DQA1*03-DQB1*03:01 or DQA1*03-DQB1*03:02; SE-encoding DRB1*04:04 participates in the formation of DQA1*03-DQB1*03:02 haploids.\(^{28}\) In addition, differential peptide binding can be found between some HLA-DQ and SE-encoding HLA-DRB1 molecules.\(^{29}\) Therefore, the molecular mechanism by which HLA-SE molecule influence RA may be more complicated than the original SE hypothesis.

Scholars performed DRB1 genotyping of 96 adult onset Still’s disease (AOSD) patients and 1026 healthy controls and found that DRB1*15:01 has a disease-inducing effect and that DRB1*09:01 has a protective effect, suggesting a protective effect of amino acid residues 86 and 98 of the DRβ chain.\(^{30}\) In that study, patients with ME芙 gene mutations showed susceptibility to DR5-induced AOSD, while patients without ME芙 mutations did not show susceptibility to DR5-induced AOSD, and DR5 patients often presented AOSD associated with macrophage activation syndrome (MAS). DR5 is a broad-spectrum antigen serotype and can be further divided into HLA-DR11, DRB1*11:01, and HLA-DR12.\(^{31}\) Studies on systemic juvenile idiopathic arthritis (sJIA) suggest that there is a strong correlation between HLA-DRB1*11 and sJIA and that the DRB1 allele is the main risk factor for sJIA.\(^{32,33}\) Both sJIA and AOSD are autoinflammatory diseases cause by abnormalities in the innate immune system,\(^{34}\) and their clinical features and HLA profile are also similar.

The results reported by Jung et al.\(^{35}\) indicated that the proportion of HLA-DP and HLA-DR lymphocytes in AOSD patients was significantly higher than that in RA and HC patients, while the proportion of HLA-DQ cells in AOSD patients was significantly lower than that in RA and HC patients. In patients, the level of HLA-DP is significantly correlated with the level of lactate dehydrogenase (LDH). The expression of HLA-DR is positively correlated with interleukin (IL)-23, the erythrocyte sedimentation rate, and IL-18. The expression of HLA-DQ is negatively correlated with white blood cells, hemoglobin, and IL-17.

Recent studies have shown that HLA class II molecules are related to many diseases, such as autoimmunity, allergies, and various infections,\(^{36}\) most of which are related to DQ and DR, with DP having less of an impact. Some scholars have studied the difference between DR and DQ, and the results suggest that HLA-DQ binds more human epitopes than does DR molecules; HLA-DQ binds pathogen epitopes that are more similar to human proteins than those bound by DR; HLA-DQ...
HLA class I molecules. KIR participates in the activation and inhibition of natural killer (NK) cells by recognizing HLA class I molecules. HLA-B51 and other HLA molecules related to BD have a common Bw4 epitope, and the interaction with its receptor KIR3DL1/DS1 plays an important role in the pathogenesis of BD.46 Some scholars have studied the relationship between BD and KIR3DL1/DS1 gene functional polymorphism, and the results suggested that HLA-B51 is a risk factor for BD, HLA-3/11 plays a protective role, Bw4 and Bw4-801 are risk factors, but with a lower risk than that for B51,47 and the receptor for HLA-A3 and A11 is KIR3DL2.48 HLA-B27 and B51, which are closely associated with ankylosing spondylitis (AS), can effectively activate KIR3DL1 NK cells, a process that may play an important role in AS. Studies of psoriatic disease and AS have also shown the protective effect of the KIR3DL1*004 allele.49,50 In addition, studies have found that KIR2DL2 is highly correlated with the occurrence and development of systemic sclerosis (SSc).51

In SSc studies, it was found that the serum HLA-G (sHLA-G) levels in SSc patients with human herpesvirus-6 (HHV-6) infection were significantly increased and that the production of sHLA-G in endothelial cells can possibly inhibit angiogenesis in the presence of a viral infection.52 Elevated plasma sHLA-G levels in SSc patients may be a marker of disease severity. Another related clinical study reported that the skin and blood HLA-G levels in SSc patients were significantly different from those in the control group.53 A study of skin tissue from 35 patients with untreated early diffuse SSc found local infiltration of CD4+ CTLs, causing apoptotic cell accumulation because of restriction by HLA class II molecules, leading to tissue damage and fibrotic reconstruction and subsequently causing abnormal functions. SSc skin biopsies revealed that CD4+ CTLs accumulated near endothelial tissues, HLA class II molecules were upregulated, and endothelial cells were the target cells for apoptosis and HLA class II upregulation.54

IgG4-related disease (IgG4-RD) is also a chronic, immune-mediated fibrotic disease, characterized by tumor-like inflammatory masses, which tend to accumulate in lacrimal glands, salivary glands, the pancreas, bile ducts, and retroperitoneal tissues. It is also closely associated with HLA.55

### 4 OTHER SYSTEMIC IMMUNE DISEASES

In addition to connective tissue diseases, autoimmune diseases are widespread in other systems. In studies of multiple sclerosis (MS), it has been found that in European populations, MS is associated with the HLA-DR*15 and DQ*06 haplotypes,56,57 and in Sardinian populations, MS is associated with the HLA-A*30, B*18, C*05, and DR*03 extended haplotypes and the HLA-DR*03 and HLA-DQ*02 alleles.58,59 Melis et al.60 applied a statistical entropy method and showed that the HLA entropy in a relapsing-remitting multiple sclerosis (RRMS) group was significantly higher than that in the control group (p = .002). Similar findings were identified for KIR entropy, but the level of significance was low (p = .043). There was no significant difference between patients with primary progressive multiple sclerosis (PPMS) and the control group. Combined with an analysis of the HLA and KIR systems, the total entropy of RRMS patients was significantly higher than that of the control group (p = .001), while the total entropy of the healthy control group and PPMS patients was not significantly different. Therefore, patients with PPMS may lack susceptible HLA haplotypes or alleles. In addition, the application of this method has also revealed that HLA and KIR are associated with the occurrence and development of type 1 diabetes, Hashimoto’s thyroiditis, celiac disease (CD), psoriasis, RA, and systemic lupus erythematosus.

A Japanese study performed KIR gene, HLA I and HLA II allele analysis on 154 patients with autoimmune hepatitis (AIH) and 201 healthy individuals. The results
suggested that the KIR3DL1/HLA-B Bw4-80Ile and HLA-
DRB1*04:05-DQB1*04:01 haplotypes were significantly
 correlated with AIH. In contrast, KIR3DL1/HLA-B Bw4-
80Thr and KIR2DL1/HLA-C2 had significant protective
effects. In general, KIR3DL1/HLA-B Bw4 represents a
new KIR/HLA pair associated with a good prognosis of
patients with AIH, while KIR3DL1/HLA-B Bw4-negative
patients may have a poor prognosis. In addition, in ulcercative colitis (UC) research, it was found that
KIR2DL1/HLA-C2 is related to UC.51

Hashimoto’s thyroiditis (HT) is also a common au-
otimmune disease. A recent study analyzed thyroid tissue
samples from 46 patients. Compared with the control
group, the HT group had significantly more HLA class I
molecule-positive samples, and the semi-quantitative
score for HLA class I molecule expression was
significantly higher.62

Noninfectious uveitis (NIU) is currently considered to
be an autoimmune uveitis. It often develops into sponta-
nous recurrent inflammation and is mediated by CD4\(^+\) T lymphocytes and proinflammatory cytokines.
Crabtree et al.,63 in rats, administered a single intravitreal
injection of AAV particles containing complementary
DNAs encoding HLA-G1 and HLA-G5 subtypes, before
simulated inducing NIU and then induced experimental
autoimmune uveitis (EAU). The clinical and histo-
pathological inflammation scores were significantly re-
duced in target eye tissues with AAV-mediated HLA-G1
and G5 gene expression compared with the contralateral
EAU eye without injection. This result suggests that
AAV-HLA-G1/5-targeted ocular gene delivery may re-
duce off-target risks and can establish long-term im-
munosuppression and that AAV-HLA-G1/5 gene therapy
can reduce the inflammatory response in EAU rats.

Bullous pemphigoid (BP) can be induced by dipeptidyl
peptidase-4 inhibitor (DPP-4I). DPP-4I can alter immu
neregulation by inhibiting DPP-4, leading to au-
toimmune diseases. The immunological characteristics
of HLA-DQB1*03:01 may be biomarkers of genetic sus-
cceptibility to DPP-4I-BP.64 HLA-DQB1*03:01 has a strong
correlation with noninflammatory DPP-4I-BP in Japa-
nese patients.65 In terms of genetic susceptibility, Sun
et al.66 emphasized the importance of HLA-DQB1*03:01
in the occurrence and development of BP, as this allele
was detected in about half of BP patients, while HLA-
DQB1*03:03 and HLA- DQB1*06:01 were alleles with
significant protective effects.

CD is a systemic immune disease. The intake of
gluten in the diet of susceptible people may trigger the
MHC class II molecular heterodimers DQ2 and
DQ8, encoded by specific HLA-DQ allele variants
(DQA1*0501-DQB1*02 and DQA1*0301-DQB1*0302), in
this population.67 Some studies have emphasized that the
HLA-DQB1 locus, especially the HLA-DQB1*02 allele,
plays a more important role. Regardless of other HLA-
DQ alleles, diploid HLA-DQB1*02 is highly correlated
with children’s CD, and haploid HLA-DQB1*02 sig-
nificantly increases the occurrence of CD.68,69 A recent
study involving gene sequencing and HLA-DQB1 gene
frequency in CD-susceptible populations in Kazakhstan
led to findings similar to those for populations in coun-
tries with a high incidence of CD.70

In sarcoidosis, there are many characteristic HLA genes
that encode class I HLA-A and B molecules and class II
HLA-DPB1, DQB1, DRB1, and DRB3 molecules. A recent
study that sequenced susceptibility sites for sarcoidosis
patients found that in Finnish patients with sarcoidosis,
the HLA-DRB1*03:01 and HLA-DRB1*04:01-DRB1*04:01
haplotypes suggest a good prognosis.71 In addition, some
studies suggest that both sarcoidosis and Sjogren’s syn-
drome are associated with the HLA-DR3 gene.72

Current studies suggest that there are immune factors
involved in the onset and outcome of Parkinson’s
disease73,74 and that the level of HLA-DR expression in
patient monocytes is closely related to better cognitive
function, semantic fluency, and motor function. In contrast,
the results of studies that used animal models of Parkinson’s
disease involving acute toxins, protein injections, and
pathological abnormalities indicated that increased HLA-DR
can have harmful effects.75,76 Some scholars speculate that it
may be because in animal models, effects such as HLA-DR-
promoted inflammatory factor release have a greater impact
than the beneficial effects of antigen presentation and
pathological protein clearance; however, in chronic clinical
patients, the beneficial effect of increased HLA-DR
in mediating pathological clearance is greater than the
harmful effect.73

5 | TUMOR IMMUNITY

Abnormalities in MHC participate in the immune escape
mechanism of tumor cells, a mechanism that has been
observed in various tumors. Researchers have detected
the expression of MHC class I and class II proteins on the
surface of tumor cells in 181 untreated melanoma pa-
patients, analyzed their transcription levels and genomes,
and investigated the relationship between MHC and the
clinical response to anti-CTLA-4 therapy, anti-PD-1
therapy or combined treatment. The results showed
that the response to anti-CTLA-4 treatment requires
melanoma cells to strongly express MHC class I mole-
cules, while the response to anti-PD-1 treatment is re-
lated to IFN-γ-mediated immune activation, including
the expression of MHC class II molecules and innate
immunity produced when MHC class I molecules are
immune compromised. In a study of autologous dendritic cell therapy for malignant mesothelioma, after patients with mesothelioma received autologous dendritic cell therapy, the expression of HLA-DR on peripheral CD4+ T cells increased. Studies using the A20 B-cell lymphoma cell line and the B16 melanoma cell line showed that antigen secretion by tumor cells and the indirect presentation of antigen-presenting cells play key roles in the rejection of tumor cells by CD4+ T cells. MHC class II molecules on the surface of tumor cells participate in this process but do not play a critical role.

In addition, studies have shown that the expression of MHC class II transactivator (CIITA) in EB virus-positive diffuse large B-cell lymphoma (DLBCL) is significantly reduced compared with that in EB virus-negative DLBCL and that gene aberrations involving CIITA are more common in EBV + DLBCL.

### 6 | INFECTIOUS DISEASES

A study of HBV infection among 1440 Argentines showed that the infection rate in central Argentina was low, while the infection rate in northwest Argentina was moderate; however, there was no obvious genetic difference between healthy and infected people. In the infected persons in these two regions, three SNPs were detected: rs3077 (HLA-DPA1), rs9277542 (HLA-DPB1), and rs7453920 (HLA-DQB2); these

| Class I | HLA genotypes | Disease |
|---------|----------------|---------|
| Classical | HLA-A*0201 | Aplastic anemia (AA) |
|          | HLA-A*0206 | |
|          | HLA-A*3101 | |
|          | HLA-A*4002 | |
|          | HLA-B*5401 | |
|          | HLA-A*2601 | Behçet's Disease (BD) |
|          | HLA-B*51 | |
|          | HLA-A3(protective) | |
|          | HLA-A11(protective) | |
|          | HLA-B*27 | |
|          | HLA-B*51 | |
|          | HLA-A*30 | |
|          | HLA-B*18 | |
|          | HLA-C*05 | |
|          | HLA-B*08(protective) | |
|          | HLA-C*07 | |
|          | HLA-B*41 | |
|          | KIR2DS1/HLAC2 | |
|          | KIR2DL3/HLA-C1/C2(protective) | |
|          | KIR2DL1/HLA-C1/C2(protective) | |
|          | KIR3DL1/HLA-B Bw4-80Ile | |
|          | KIR3DL1/HLA-B Bw4-80Thr(protective) | |
|          | KIR2DL1/HLA-C2(protective) | |
|          | KIR3DL1/HLA-B Bw4(protective) | |
|          | KIR2DL1/HLA-C2 | |
| Nonclassical | HLA-E*0101 | Graft-versus-host disease (GVHD) |
|            | HLA-A*0103 | |
|            | sHLA-E | |
|            | HLA-G | |
|            | sHLA-G | |
|            | HLA-G1 | |
|            | HLA-G5 | |
|            | HLA-G | |
|            | HLA-G | |

Abbreviation: HLA, human leukocyte antigen.
SNPs were significantly related to anti-chronic HBV infection factors and virus clearance factors, and SNP rs2856718 (HLA-DQB1) was significantly related to susceptibility to chronic HBV infection.80

### Table 2 - Genotypes of HLA class II antigens affecting the occurrence and development of immune-related diseases

| Class II | HLA genotypes | Disease |
|----------|----------------|---------|
| Classical | HLA-DRB3*0101 | Fetal and neonatal alloimmune thrombocytopenia (FNAIT) |
|          | HLA-DRB1*0402(protective) | Rheumatoid arthritis (RA) |
|          | HLA-DRB1*0103(protective) | |
|          | HLA-DRB1*1301(protective) | |
|          | HLA-DRB3*1302(protective) | |
|          | HLA-DRA1*03 | |
|          | HLA-DRB1*0301 | |
|          | HLA-DRB1*0302 | |
|          | HLA-DRB1*1501 | |
|          | HLA-DRB1*0901 (protective) | |
|          | HLA-DP | |
|          | HLA-DR5 | |
|          | HLA-DRB1*1101 | |
|          | HLA-DR12 | |
|          | HLA-DR15 | |
|          | HLA-DR*06 | |
|          | HLA-DQ*02 | |
|          | HLA-DQB1*0301 | |
|          | HLA-DQB1*0303 (protective) | |
|          | HLA-DQB1*0601 (protective) | |
|          | HLA-DR | |
|          | HLA-DRB1*04:05 | |
|          | DQB1*04:01 | |
|          | HLA-DQA1*0501 | |
|          | HLA-DQB1*02 | |
|          | HLA-DQA*0301 | |
|          | HLA-DQB1*0302 | |
|          | HLA-DRB1*0301(protective) | |
|          | HLA-DRB1*0401(protective) | |
|          | HLA-DPB1*0401(protective) | |
|          | HLA-DR3 | |
|          | HLA-DR3 | |
|          | HLA-DPB2 | |
|          | HLA-DQB1 | |
|          | HLA-DQA1 | |
|          | HLA-DPA1 | |
|          | HLA-DPB1 | |
|          | HLA-DRB | |
|          | HLA-DQB1*0501 | |
|          | HLA-DQB1*0502 | |
|          | HLA-DR*1502 | |
|          | HLA-DR*1602 | |
| Nonclassical | HLA-DOB | Hepatitis B (HBV) virus infection |

Abbreviation: HLA, human leukocyte antigen.

In addition, the results of studies on the correlation between delayed HBeAg seroconversion and immune-related gene loci in patients with chronic hepatitis B showed that the expression of rs2621377 (HLA-DOB) and
rs3130215 (HLA-DPB2) was significantly related to delayed spontaneous e antigen seroconversion, of which rs2621377 (HLA-DOB) was an independent risk factor for delayed spontaneous e antigen seroconversion. Studies have shown that HLA-DQB1 and HLA-DQA1 are associated with early HBeAg seroconversion in children with chronic hepatitis B and that the genetic variations in the HLA-DPA1 (rs3077), HLA-DPB2 (rs9366816), and HLA-DPB1 (rs2281388 and rs9277535) loci are significantly correlated with HBV infection, especially with HBV breakthrough in children. In a study of hepatitis C, some scholars have proposed that the genetic variation in HLA-DO may be crucial to the outcome of hepatitis C virus treatment in the Chinese Han population.

Researchers have studied the relationship among HLA-B, HLA-C and KIR genotypes, HIV-1 infection, and immune reconstitution inflammatory syndrome (IRIS) in tuberculosis and HIV-coinfected patients. The results showed that KIR2DS2 is associated with an increased risk of tuberculosis; HLA-B*08 is a protective factor against the onset of tuberculosis; not carrying KIR2DL3 and carrying HLA-C*07 are related to the antituberculosis ability of HIV-infected patients; and the increased risk of IRIS is associated with carrying the KIR2DS2 gene, the HLA-B*41 allele and the KIR2DS1 + HLA-C2 gene pair and with not carrying the KIR2DL3 + HLA-C1/C2 gene pair and KIR2DL1 + HLA-C1/C2 gene pair. SNPs in MHCII-DRB regulatory genes related to the clinical results of malaria in patients infected with Plasmodium have been investigated. The results showed that the GTAT haplotype has high DRB transcriptional activity, leading to increased DRB expression and subsequent interference in antigen expression and T-cell activation and thereby causing lower levels of parasitaemia than other haplotypes (GTAC and GGGT). In addition, it is suggested that HLA-G plays an important role in various parasitic infectious diseases.

In addition, a study of anti-interferon-γ antibodies in Southeast Asian populations showed that these antibodies are closely related to HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 and thus related to infection by invasive non-tuberculosis mycobacterial infections and intracellular opportunistic pathogens.

7 | ORGAN TRANSPLANTATION AND REPRODUCTIVE IMMUNITY

Recently, in the field of organ transplantation and reproductive immunity, there have been many studies on nonclassical HLA molecules. For HLA-E, most studies have focused on the two most common genotypes (HLA-E*01:01 and HLA-E*01:03). In addition, Kordelas et al. analyzed soluble HLA-E (sHLA-E) and found that reduced sHLA-E levels in patients after allogeneic hematopoietic stem cell transplantation are associated with severe acute and long-term chronic graft-versus-host disease and lower overall survival rates; however, no association was found with the three most common HLA-E genotypes (HLA-E*01:03/*01:03, HLA-E*01:01/*01:01, and HLA-E*01:01/*01:03).

HLA-G is another nonclassical HLA molecule that has been studied frequently. HLA-G and HLA-E are expressed on trophoblast cells during pregnancy, and they promote tolerance towards the “semi-allogeneic” fetus by binding to inhibitory receptors on NK cells. HLA-G and HLA-E interact to establish an immunosuppressive microenvironment, which helps to avoid tumor surveillance.

Studies have shown that curcumin stimulates angiogenesis through vascular endothelial growth factor (VEGF) and increases the expression of HLA-G in placental trophoblasts during human early pregnancy, thereby promoting cell growth and migration and stimulating angiogenesis.

Tables 1 and 2, respectively, summarize the new research progress on the roles of HLA class I and class II molecules in the occurrence and development of immune-related diseases. Summarizing the above research progress, HLA is an important research topic that bridges immunology and clinical diseases. With the development of research methods and technologies, there will be more discoveries and broader prospects.

ACKNOWLEDGMENT
This study was supported by the National Natural Science Foundation of China (81970115, 81800120, 81870101, 81800119, 81900125, and 81970116).

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT
All the data used to support this study are available from the corresponding author upon request.

ORCID
Bingnan Liu http://orcid.org/0000-0002-1938-4679

REFERENCES
1. Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14:301-323.
2. van Drongelen V, Holoshitz J. Human leukocyte antigen-disease associations in rheumatoid arthritis. Rheum Dis Clin North Am. 2017;43(3):363-376.
3. El-Awar N, Jucaud V, Nguyen A, Epitopes HLA. The targets of monoclonal and alloantibodies defined. *J Immunol Res*. 2017;2017:3406230.

4. Busch R, Kollnberger S, Mellins ED. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. *Nat Rev Rheumatol*. 2019;15(6):364-381.

5. Katagiri T, Sato-Otsuibo A, Kashiwase K, et al. Marrow donor, frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. *Blood*. 2011;118(25):6601-6609.

6. Imi T, Katagiri T, Hosomichi K, et al. Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. *Blood Adv*. 2018;2(9):1000-1012.

7. Maruyama H, Katagiri T, Kashiwase K, et al. Clinical significance and origin of leukocytes that lack HLA-A allele expression in patients with acquired aplastic anemia. *Exp Hematol*. 2016;44(10):931-939 e3.

8. Zaimoku Y, Takamatsu H, Hosomichi K, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. *Blood*. 2017;129(21):2908-2916.

9. Inaguma Y, Akatsuka Y, Hosokawa K, et al. Induction of HLA-B*40:02-restricted T cells possessing cytotoxic and suppressive functions against haematopoietic progenitor cells from a patient with severe aplastic anaemia. *Br J Haematol*. 2016;172(1):131-134.

10. Espinoza JL, Elbadry MI, Chonabayashi K, et al. Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. *Blood Adv*. 2018;2(4):390-400.

11. Elbadry MI, Mizumaki H, Hosokawa K, et al. Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anaemia. *Haematologica*. 2019;104(10):e447-e450.

12. Kikkawa E, Shiina T, Shigenari A, et al. Detection of 6pLOH in an aplastic anaemia patient by in phase HLA genotyping. *HLA*. 2020;95(5):465-469.

13. Kjeldsen-Kragh J, Ahlen MT. Foetal and neonatal alloimmune thrombocytopenia—the role of the HLA-DRB3*01:01 allele for HPA-1a-immunization and foetal/neonatal outcome. *Transfus Apher Sci*. 2020;59(1):102707.

14. Kjeldsen-Kragh J, Olsen KJ. Risk of HPA-1a-immunization in HPA-1a-negative women after giving birth to an HPA-1a-positive child. *Transfus*ation. 2019;59(4):1344-1352.

15. Delbos F, Bertrand G, Croisille L, Ansart S, et al. DR molecules differently associated with anti-citrullinated protein antibody-positive rheumatoid arthritis in four European populations. *Arthritis Rheum*. 2010;62(5):1236-1245.

16. Scholz E, Mestre-Ferrer A, Daura X, et al. A comparative analysis of the peptide repertoires of HLA-DR molecules differentially associated with rheumatoid arthritis. *Arthritis Rheum*. 2016;68(10):2412-2421.

17. Plenge RM. Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. *Curr Opin Rheumatol*. 2009;21(3):262-271.

18. Zanelli E, Breedveld FC, de Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. *Hum Immunol*. 2000;61(12):1254-1261.

19. Veld P, van der Helm van Mil AH, Huizinga TW, Schreuder GM, Breedveld FC, de Vries RR, Toes RE. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. *Arthritis Rheum*. 2005;52(9):2637-2644.

20. van der Woude D, Lie BA, Lundström E, et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. *Arthritis Rheum*. 2010;62(5):1236-1245.

21. van der Woude D, Lie BA, Lundström E, et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. *Arthritis Rheum*. 2010;62(5):1236-1245.

22. Scholz E, Mestre-Ferrer A, Daura X, et al. A comparative analysis of the peptide repertoires of HLA-DR molecules differentially associated with rheumatoid arthritis. *Arthritis Rheum*. 2016;68(10):2412-2421.

23. Plenge RM. Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. *Curr Opin Rheumatol*. 2009;21(3):262-271.

24. Zanelli E, Breedveld FC, de Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. *Hum Immunol*. 2000;61(12):1254-1261.

25. Kampstra AS, van Heemst J, Moustakas AK, Papadopoulos GK, Huizinga TW, Toes RE. The increased ability to present citrullinated peptides is not unique to HLA-SE molecules: arginine-to-citrulline conversion also enhances peptide affinity for HLA-DQ molecules. *Arthritis Res Ther*. 2016;18(1):254.

26. Asano T, Furukawa H, Sato S, et al. Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still’s disease. *Arthritis Res Ther*. 2017;19(1):199.

27. Furukawa H, Oka S, Kawasaki A, et al. Human leukocyte antigen and systemic sclerosis in Japanese: the sign of the four independent protective alleles, DRB1*1302, DRB1*1406, DQBI*03:01, and DPBI*02:01. *PLOS One*. 2016;11(4):e0154255.

28. Ombrello MJ, Remmers EF, Tachmazidou I, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. *Proc Natl Acad Sci USA*. 2015;112(52):15970-15975.
33. Nonaka F, Migita K, Jiuchi Y, et al. Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still’s disease. Clin Exp Immunol. 2015;179(3):392-397.

34. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931-934.

35. Jung JY, Choi B, Sayeed HM, et al. Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease. Int J Immunopathol Pharmacol. 2018;32:2058738418791284.

36. Kames JH, Bastarache L, Shaffer CM, et al. Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci Transl Med. 2017;9(389):eaai8708.

37. Manczinger M, Kemeny L. Peptide presentation by HLA-DQ molecules is associated with the development of immune tolerance. Peeri. 2018;6:e5118.

38. Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018;18(5):325-339.

39. Glanville J, Huang H, Nau A, et al. Identifying specificity groups in the T cell receptor repertoire. Nature. 2017: 547(7661):94-98.

40. van Lummel M, Duijkerken G, van Veelen PA, et al. Post-translational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes. 2014;63(1):237-247.

41. Takeuchi M, Mizuki N, Meguro A, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet’s disease susceptibility. Nature Genet. 2017; 49(3):438-443.

42. Nakamura J, Meguro A, Ishii G, et al. The association analysis between HLA-A*26 and Behçet’s disease. Sci Rep. 2019;9(1):4426.

43. Kato H, Takeuchi M, Horita N, et al. HLA-A26 is a risk factor for Behçet’s disease ocular lesions. Modern Rheumatology. 2020;31:1-5.

44. Horie Y, Meguro A, Ohta T, et al. HLA-B51 carriers are susceptible to ocular symptoms of Behçet disease and the association between the two becomes stronger towards the east along the silk road: a literature survey. Ocul Immunol Inflamm. 2017;25(1):37-40.

45. Mizuki Y, Horita N, Horie Y, et al. The influence of HLA-B51 on clinical manifestations among Japanese patients with Behçet’s disease: a nationwide survey. Modern Rheumatol. 2020;30(4):708-714.

46. Petrushkin H, Hasan MS, Stanford MR, Fortune F, Wallace GR. Behçet’s disease: do natural killer cells play a significant role? Front Immunol. 2015;6:134.

47. Castano-Nunez A, Montes-Can MA, Garcia-Lozano JR, et al. Association of functional polymorphisms of KIR3DL1/DS1 with Behçet’s disease. Front Immunol. 2019;10:2755.

48. Augusto DG, O’Connor GM, Lobo-Alves SC, et al. Pemphigus is associated with KIR3DL2 expression levels and provides evidence that KIR3DL2 may bind HLA-A3 and A11 in vivo. Eur J Immunol. 2015;45(7):2052-2060.

49. Ahn RS, Mosleh I, Martin MP, et al. Inhibitory KIR3DL1 alleles are associated with psoriasis. Br J Dermatol. 2016;174(2):449-451.

50. Berinstein J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Gladman DD. Association of variably expressed KIR3DL1 alleles with psoriatic disease. Clin Rheumatol. 2017;36(10):2261-2266.

51. Machado-Sulbaran AC, Ramirez-Dueñas MG, Navarro-Zarza JE, et al. KIR/HLA gene profile implication in systemic sclerosis patients from Mexico. J Immunol Res. 2019;2019:6808061.

52. Caselli E, Soffritti I, D’Accolti M, et al. HHV-6A infection and systemic sclerosis: clues of a possible association. Microorganisms. 2019;8(1):39.

53. Favoino E, Favia IE, Vettori S, et al. Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis. Clin Exp Immunol. 2015;181(1):100-109.

54. Maehara T, Kaneko N, Perugino CA, et al. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest. 2020;130(5):2451-2464.

55. Borges T, Silva S. IgG4-related disease: how to place it in the spectrum of immune-mediated and rheumatologic disorders? Modern Rheumatol. 2020;30(4):609-616.

56. Kaushansky N, Altman DM, David CS, Lassmann H, Ben-Nun A. DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). J Neuroinflammation. 2012;9:29.

57. Sawyer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-219.

58. Marrosu MG, Murru R, Murru MR, et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Gen. 2001;10(25):2907-2916.

59. Pastorino R, Menni C, Barca M, et al. Association between protective and deleterious HLA alleles with multiple sclerosis in Central East Sardinia. PLOS One. 2009;4(8):e5626.

60. Melis M, Littera R, Cocco E, et al. Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: a pilot study on multiple sclerosis. PLOS One. 2019;14(12):e0226615.

61. Saito H, Hirayama A, Umemura T, et al. Association between KIR-HLA combination and ulcerative colitis and Crohn’s disease in a Japanese population. PLOS One. 2018;13(4):e0195778.

62. Weider T, Richardson SJ, Morgan NG, Paulsen TH, Dahl-Jorgensen K, Hammerstad SS. Upregulation of HLA class I and antiviral tissue responses in Hashimoto’s thyroiditis. Thyroid. 2020;30(3):432-442.

63. Crabtree E, Song L, Llanga T, et al. AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis. Sci Rep. 2019;9(1):19864.

64. Hibi A, Kasahara Y, Ishihara Y, Hata K, Hosokawa N, Nakagawa T. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01. CEN Case Rep. 2020;9(3):189-194.

65. Ujiie H, Muramatsu K, Mushiroda T, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous Pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018;138(5):1201-1204.

66. Sun Y, Liu H, Wang Z, et al. The HLA-DQB1*03:01 is associated with bullous pemphigoid in the Han Chinese population. J Invest Dermatol. 2018;138(8):1874-1877.

67. Lindfors K, Ciacci C, Kurppa K, et al. Coeliac disease. Nat Rev Dis Primers. 2019;5(1):3.
68. De Silvestri A, Capitini C, Poddighe D, et al. HLA-DQ genetics in children with celiac disease: a meta-analysis suggesting a two-step genetic screening procedure starting with HLA-DQ β chains. Pediatr Res. 2018;83(3):564-572.
69. Capitini C, De Silvestri A, Rebuffi C, Tinelli C, Poddighe D. Relevance of HLA-DQB1*02 allele in the genetic predisposition of children with celiac disease: additional cues from a meta-analysis. *Medicina (Kaunas)*. 2019;55(5):190.
70. Poddighe D, Turganbekova A, Baymukasheva D, Saduakas Z, Zhanzakova Z, Abdakhmanova S. Genetic predisposition to celiac disease in Kazakhstan: potential impact on the clinical practice in Central Asia. *PLOS One*. 2020;15(1):e0226546.
71. Lahtela E, Kankainen M, Sinisalo J, Selroos O, Lokki ML. Exome sequencing identifies susceptibility loci for sarcoidosis prognosis. *Front Immunol*. 2019;10:2964.
72. Santiago T, Santiago M, Rovisco J, et al. Coexisting primary Sjögren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome? *Rheumatol Int*. 2014;34(11):1619-1622.
73. Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, et al. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease. *Brain Behav Immun*. 2020;87:473-488.
74. Zhao J, Han X, Xue L, Zhu K, Liu H, Xie A. Association of TLR4 gene polymorphisms with sporadic Parkinson’s disease in a Han Chinese population. *Neural Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol*. 2015;36(9):1659-1665.
75. Williams GP, Schonhoff AM, Jurkuvnaite A, Thome AD, Standaert DG, Harms AS. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson’s disease. *J Neuroinflammation*. 2018;15(1):244.
76. Harms AS, Cao S, Rowe AL, et al. MHCI is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration, *J Neurosci Off J Soc Neurosci*. 2013;33(23):9592-9600.
77. de Goeje PL, Klaver Y, Kajen-Lambers MEH, et al. Auto- logous dendritic cell therapy in mesothelioma patients enhances frequencies of peripheral CD4 T cells expressing HLA-DR, PD-1, or ICOS. *Front Immunol*. 2018;9:2034.
78. Haabeth OAW, Fauskanger M, Manzke M, et al. CD4(+) T-cell-mediated rejection of MHC class II-positive tumor cells is dependent on antigen secretion and indirect presentation on host APCs. *Cancer Res*. 2018;78(16):4573-4585.
79. Jiang XN, Yu BH, Yan WH, Lee J, Zhou XY, Li XQ. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression. *Oncoimmunology*. 2020;9(1):1683346.
80. Trinks J, Nishida N, Hulianiuk ML, et al. Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. *Liver Int*. 2017;37(10):1476-1487.
81. Liu WC, Wu IC, Chiu YC, et al. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients. *Antiviral Res*. 2020;176:104719.
82. Wang L, Zou ZQ, Wang K. Clinical relevance of HLA gene variants in HBV infection. *J Immunol Res*. 2016;2016:9069375-9069377.
83. Fan J, Huang X, Chen J, et al. Host genetic variants in HLA loci influence risk for hepatitis B virus infection in children. *Hepatitis Monthly*. 2016;16(8):e37786.
84. Yao Y, Liu M, Zang F, et al. Association between human leuko cyte antigen-DR polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study. *BMJ Open*. 2018;8(4):e019406.
85. de Sa NBR, Ribeiro-Alves M, da Silva TP, et al. Clinical and genetic markers associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes. *BMC Infect Dis*. 2020;20(1):59.
86. Sar P, Agarwal A, Vadodariya DH, Kariya H, Khuman J, Dalai S. MHC class II (DRB) promoter polymorphism and its role in parasite control among malaria patients. *J Immunol*. 2020;204(4):943-953.
87. Sabbagh A, Sonon P, Sadissou I, et al. The role of HLA-G in parasitic diseases. *HLA*. 2018;91(4):255-270.
88. Ku CL, Lin CH, Chang SW, et al. Anti-IFN-gamma auto-antibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia. *J Allergy Clin Immunol*. 2016;137(3):945-948 e8.
89. Kordelas L, Schwich E, Lindemann M, et al. Decreased soluble human leukocyte antigen E levels in patients after allogeneic hematopoietic stem cell transplantation are associated with severe acute and extended chronic graft-versus-host disease and inferior overall survival. *Front Immunol*. 2020;10.
90. Hirsch ML, Conatser LM, Smith SM, et al. AAV vector-mediated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis. *Sci Rep*. 2017;7(1):17840.
91. Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. *Front Immunol*. 2014;5:394.
92. Basak S, Srinivas V, Mallepogu A, Duttaroy AK. Curcumin stimulates angiogenesis through VEGF and expression of HLA-G in first-trimester human placental trophoblasts. *Cell Biol Int*. 2020;44(5):1237-1251.